Találati lista | Tudóstér

001-es BibID:	BIBFORM065230
Első szerző:	Galimberti, Sara
Cím:	Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms / Sara Galimberti, Balint Nagy, Eugenio Ciancia, Francesco Caracciolo, Edoardo Benedetti, Matteo Pelosini, Daniele Focosi, Mario Petrini
Dátum:	2010
ISSN:	1042-8194
Megjegyzések:	Notwithstanding the most recent and effectivetherapeutic strategies, in the majority of patientsmantle cell lymphoma (MCL) is still aggressive, withmedian overall survival (OS) ranging from 26 to 57months, when patients are stratified according to themantle cell lymphoma international prognostic index(MIPI) [1,2]. Thus, several immunochemotherapycombinations have been explored to improve outcome,such as R-Hyper-CVAD (rituximab plushyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, methotrexate, cytarabine)[2], R-CHOP (rituximab plus cyclophosphamide,doxorubicin, vincristine, prednisone) [3],maxi-CHOP [4], bortezomib plus R-CHOP [5],and mTOR (mammalian target of rapamycin)inhibitors [6]. Moreover, also autologous transplantstill remains a valid therapeutic option for youngpatients responsive to dose-intensified inductionchemotherapy, with 6-year overall survival andprogression-free survival of 70% and 66%, respectively[7].
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban mantle cell lymphoma VEGF Polymorphism
Megjelenés:	Leukemia & Lymphoma 52 : 1 (2010), p. 142-144. -
További szerzők:	Nagy Bálint (1956-) (molekuláris genetikus) Ciancia, Eugenio Caracciolo, Francesco Benedetti, Edoardo Pelosini, Matteo Focosi, Daniele Petrini, Mario
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM065423
Első szerző:	Galimberti, Sara
Cím:	Evaluation of the MDR1, ABCG2, Topoisomerases IIα and GST[pi] gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen / Sara Galimberti, Balint Nagy, Edoardo Benedetti, Simone Pacini, Stefania Brizzi, Francesco Caracciolo, Federico Papineschi, Elena Ciabatti, Francesca Guerrini, Rita Fazzi, Martina Canestraro, Mario Petrini
Dátum:	2009
ISSN:	1042-8194
Megjegyzések:	The genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of otherindolent lymphoproliferative disorders, Topoisomerase IIa, glutathione-s-transferasep (GSTp) and ABCG2 (BCRP)chemoresistance genes being over-expressed in MCL. In our study, expression levels of the above mentioned genes plusMDR1 were tested on bone marrow samples from 20 patients treated with Rituximab plus hyper-CVAD regimen, in order toevaluate a possible impact of the chemoresistance phenomenon on this promising treatment regimen. All patients expressedABCG2 and MDR1 genes; 85% of cases expressed GSTp and topoisomerase IIa. Only ABCG2 were over-expressed incomparison both with marrow from healthy donors and tonsilar CD5?/CD20? lymphocytes (adopted as normal counterpart of the neoplastic population). The overall response rate of the entire series was 87.5%, with 44% of complete responses.Fifty-seven percent of patients achieved the clearance of minimal residual disease. Levels of tested genes did not condition either quality of clinical response or PFS (76% at 24 months). Nevertheless, an ABCG2 higher expression appeared associated with a worse PFS and levels of this gene paralleled the status of minimal residual disease. A further evaluation ofABCG2 expression in larger series of MCL patients would be suitable.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban MDR1 ABCG2 topoisomerases mantle cell lymphoma
Megjelenés:	Leukemia & Lymphoma. - 48 : 8 (2009), p. 1502-1509. -
További szerzők:	Nagy Bálint (1956-) (molekuláris genetikus) Benedetti, Edoardo Pacini, Simone Brizzi, Stefania Caracciolo, Francesco Papineschi, Federico Ciabatti, Elena Guerrini, Francesca Fazzi, Rita Canestraro, Martina Petrini, Mario
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM065302
Első szerző:	Nagy Bálint (molekuláris genetikus)
Cím:	RAF-1 over-expression does condition survival of patients affected by aggressive mantle cell lymphoma / Nagy Bálint, Galimberti Sara, Benedetti Edoardo, Caracciolo Francesco, Pacini Simone, Vilpo Juhani, Ferrer Anna, Elonen Erkki, Franssila Kaarle, Knuutila Sakari, Petrini Mario
Dátum:	2007
ISSN:	0145-2126
Megjegyzések:	Our results show over-expression of RAF-1 in MCL versus tonsilar B-cell population. The absence of significance versus normal bone marrows could be related to variability of neoplastic infiltration and, perhaps, to the microenvironment, that in MCL would be particularly relevant [11].The observation of a clinical prognostic significance of RAF-1 would be useful in the stratification of cases on the basis of a "biological risk".This would be particularly relevant in the context of the R-Hyper-CVAD regimen that, notwithstanding its high clinical efficacy (even in the eradicating minimal residual disease) has a not negligible toxicity (in our series, 30% of infective complications, with two patients who died because of sepsis).Consequently, if the prognostic role of RAF-1 over-expression will be confirmed in larger series of patients, different therapeutic strategies would be adopted in the treatment of MCL.In this line, Sorafenib, an oral multi-kinase inhibitor that targets also RAF kinases would be an interesting compound [12] for treatment of mantle cell lymphoma.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok levél RAF-1 overexpression mantle cell lymphoma
Megjelenés:	Leukemia Research. - 31 : 11 (2007), p. 1595-1597. -
További szerzők:	Galimberti, Sara Benedetti, Edoardo Caracciolo, Francesco Pacini, Simone Vilpo, Juhani Ferrer, Anna Elonen, Erkki Franssila, Kaarle Knuutila, Sakari Petrini, Mario
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: